| [1] |
Guo HH,Miao NN,Li TF,et al.Pharmaceutical coamorphous:a newly defined single-phase amorphous binary system[J].Prog Chem(化学进展),2014,26(2/3):478-486.
|
| [2] |
Qian S,Heng WL,Wei YF,et al.Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior[J].Cryst Growth Des,2015,15(6):2920-2928.
|
| [3] |
Gao Y,Liao J,Qi X,et al.Coamorphous repaglinide-saccharin with enhanced dissolution[J].Int J Pharm,2013,450(1/2):290-295.
|
| [4] |
Loebmann K,Strachan C,Grohganz H,et al.Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions[J].Eur J Pharm Biopharm,2012,81(1):159-169.
|
| [5] |
Qian S, Li Z, Heng WL, et al. Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride[J].RSC Adv, 2016,6(108):106396-106412.
|
| [6] |
Chavan RB,Thipparaboina R,Kumar D,et al.Coamorphous systems:a product development perspective[J].Int J Pharm,2016,515(1/2):403-415.
|
| [7] |
Chen J,Guo HH,Zhang JJ,et al.Physicochemical characteristics of coamorphous simvastatin-gliclazide[J].J China Pharm Univ(中国药科大学学报),2015,46(3):301-308.
|
| [8] |
Hernandez I,Baik SH,Pinera A,et al.Risk of bleeding with dabigatran in atrial fibrillation[J].JAMA Intern Med,2015,175(1):18-25.
|
| [9] |
Schulman S,Kearon C,Kakkar AK,et al.Extended use of dabigatran,warfarin,or placebo in venous thromboembolism[J].N Engl J Med,2013,368(8):709-718.
|
| [10] |
Daugan A,Grondin P,Ruault C,et al.The discovery of tadalafil:a novel and highly selective PDE5 inhibitor.2:2,3,6,7,12,12a-hexahydropyrazino [1′,2′:1,6] pyrido [3,4-b] indole-1,4-dione analogues[J].J Med Chem,2003,46(21):4533-4542.
|
| [11] |
Humbert M,Lau EM,Montani D,et al.Advances in therapeutic interventions for patients with pulmonary arterial hypertension[J].Circulation,2014,130(24):2189-2208.
|
| [12] |
Bendayan D,Shitrit D,Kramer MR.Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension:a pilot study[J].Respirology,2008,13(6):916-918.
|
| [13] |
Kruger S,Haage P,Breuer C,et al.Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography[J].Chest,2001,120(5):1556-1561.
|
| [14] |
Chai FJ,Sun LL,Ding YF,et al.A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability[J].Nanomedicine,2016,11(14):1801-1816.
|
| [15] |
U.S.Food and Drug Administration.Center for drug evaluation and research application number 22-5.12[EB].(2010-12-15)[2019-02-10] .http:// www.accessdata.fda.gov/ drugsatfda_ docs/ nda/ 2010/ 022512Orig1s000TOC.cfm.
|
| [16] |
Wlodarski K,Sawicki W,Haber K,et al.Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Biopharm,2015,94:106-115.
|
| [17] |
Wei YF,Ling YN,Su ML,et al.Characterization and stability of amorphous tadalafil and four crystalline polymorphs[J].Chem Pharm Bull,2018,66(12):1114-1121.
|
| [18] |
Hildebrand JH,Scott RL.The solubility of non electrolytes[M].3rd ed.New York:Reinhold Publishing Corporation,1950:153-173.
|
| [19] |
Greenhalgh DJ,Williams AC,Timmins P,et al.Solubility parameters as predictors of miscibility in solid dispersions[J].J Pharm Sci,1999,88(11):1182-1190.
|
| [20] |
Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids[J].Polym Eng Sci,1974,14(2):147-154.
|
| [21] |
Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation[J].Int J Pharm,2011,407(1/2):63-71.
|
| [22] |
Barton AFM.CRC handbook of solubility parameters and other cohesion parameters [M].2nd ed.Florida:CRC Press,1991:160-185.
|
| [23] |
Wood J,Syarto J,Letterman H.Improved holder for intrinsic dissolution rate studies[J].J Pharm Sci,1965,54(7):1068.
|
| [24] |
Wang FY,Zhang Q,Zhang ZY,et al.Solid-state characterization and solubility enhancement of apremilast drug-drug cocrystals[J].CrystEngComm,2018,20(39):5945-5948.
|
| [25] |
Lobmann K,Grohganz H,Laitinen R,et al.Amino acids as co-amorphous stabilizers for poorly water soluble drugs-part 1:preparation,stability and dissolution enhancement[J].Eur J Pharm Biopharm,2013,85(3):873-881.
|
| [26] |
Ceric H,Dogan J,Leksic E,et al.Solid state forms of dabigatran etexilate,dabigatran etexilate mysylate and processes for preparation thereof: WO,2012027543A1[P].2012-03-01 [2019-02-16] .
|
| [27] |
Wizel S,Vant A,Diller D,et al.Tadalafil crystal forms and processes for preparing them:WO,2006050458A2[P].2006-11-11 [2019-02-16] .
|
| [28] |
Yu L.Amorphous pharmaceutical solids:preparation,characterization and stabilization[J].Adv Drug Deliv Rev,2001,48(1):27-42.
|
| [29] |
Wlodarski K,Sawicki W,Paluch KJ,et al.The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil[J].Eur J Pharm Sci,2014,62:132-140.
|
| [30] |
Vyas V,Sancheti P,Karekar P,et al.Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407[J].Acta Pharm,2009,59(4):453-461.
|
| [31] |
Qian S,Wang SS,Li Z,et al.Charge-assisted bond N+-H mediates the gelation of amorphous lurasidone hydrochloride during dissolution[J].Int J Pharm,2017,518(1/2):335-341.
|
| [32] |
Guzman HR,Tawa M,Zhang Z,et al.Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations[J].J Pharm Sci,2007,96(10):2686-2702.
|
| [33] |
Raina SA,Zhang GGZ,Alonzo DE,et al.Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs[J].J Pharm Sci,2014,103(9):2736-2748.
|
本站查看
下载:
